Intervention not reported
Communication and language skills: expressive language Measured by: standardized measures of expressive language (higher scores indicate better expressive language skills) · patients with young children (less than six years old) with autism spectrum disorders (ASD)
1 finding from 1 review
Intervention not reported
Communication and language skills: receptive language Measured by: standardized measures of receptive language (higher scores indicate better receptive language skills) · patients with young children (less than six years old) with autism spectrum disorders (ASD)
1 finding from 1 review
Intervention not reported
Problem behavior Measured by: standardized parent‐report measures and checklists (lower scores indicate lower levels or less severe problem behavior) · patients with young children (less than six years old) with autism spectrum disorders (ASD)
1 finding from 1 review
Intervention not reported
Improvement in acne severity assessed by a decrease in total inflammatory lesion count, measured in participants who were treated for a minimum period of 16 weeks (Changes from baseline in total inflammatory lesion count and number of participants... · participants with moderate and severe acne
1 finding from 1 review
Intervention not reported
Frequency of serious adverse effects 20 to 24 weeks · participants with moderate and severe acne
It is very uncertain whether the intervention changes frequency of serious adverse effects 20 to 24 weeks (very low certainty).
1 finding from 1 review
Intervention not reported
Improvement in acne severity assessed by physician's global evaluation 20 to 24 weeks · participants with moderate and severe acne
1 finding from 1 review
Regression rate at 6 months · women with atypical endometrial hyperplasia
It is very uncertain whether levonorgestrel‐releasing intrauterine system (LNG‐IUS) changes regression rate at 6 months compared with medroxyprogesterone (MPA) 10 mg (very low certainty).
1 finding from 1 review
Nausea · women with atypical endometrial hyperplasia
It is very uncertain whether levonorgestrel‐releasing intrauterine system (LNG‐IUS) changes nausea over 6‐month compared with medroxyprogesterone (MPA) 10 mg (very low certainty).
1 finding from 1 review
Vaginal bleeding over 6‐month · women with atypical endometrial hyperplasia
Levonorgestrel‐releasing intrauterine system (LNG‐IUS) may leads to higher vaginal bleeding over 6‐month compared with medroxyprogesterone (MPA) 10 mg (low certainty).
1 finding from 1 review
Parental sensitivity · caregiver‐infant dyads
1 finding from 1 review
Caregiver depression ( · caregiver‐infant dyads
Summary of findings: NBAS or NBO showed no clear difference in caregiver mental health (depression), dichotomous data Assessed at… compared with control (low certainty).
1 finding from 1 review
Infant social, emotional, cognitive and motor development Assessed when infant aged 4 months, using the BSID; higher scores indicate better development · caregiver‐infant dyads
1 finding from 1 review
Caregiver perception of infant (parents' perception of the degree of difficult temperament of the infant) Assessed at postintervention, 8 weeks after delivery; higher score indicates better outcome · caregiver‐infant dyads
1 finding from 1 review
Caregiver stress (maternal perceptions of her adjustment to the parenting role) Assessed when infant aged 4 months, using the PSI · caregiver‐infant dyads
1 finding from 1 review
Caregiver knowledge (related to infants' physical capacities, including reflexes and senses) Assessed at postintervention, using multiple choice factual questions; higher scores indicate better outcome · caregiver‐infant dyads
1 finding from 1 review
Intervention not reported
The ability of OWSC, when seen to reach the colon on · Adults 18 yrs and over with malignant bowel obstruction (MBO) as defined by the International Conference on MBO, with no indication for…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
The rate of resolution of MBO with medical management only in patients receiving OWSC compared with those not receiving it (therapeutic). · Adults 18 yrs and over with malignant bowel obstruction (MBO) as defined by the International Conference on MBO, with no indication for…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Gastrointestinal adverse effects (increased abdominal pain, nausea, vomiting). · Adults 18 yrs and over with malignant bowel obstruction (MBO) as defined by the International Conference on MBO, with no indication for…
1 finding from 1 review
no estimate extracted
1 study · 9 participants
Very low
Intervention not reported
Extra‐abdominal complications (aspiration pneumonia, hypersensitivity reactions). · Adults 18 yrs and over with malignant bowel obstruction (MBO) as defined by the International Conference on MBO, with no indication for…
1 finding from 1 review
no estimate extracted
1 study · 9 participants
Very low
Intervention not reported
Length of hospital stay. · Adults 18 yrs and over with malignant bowel obstruction (MBO) as defined by the International Conference on MBO, with no indication for…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found